Orchid Pharma Ltd Company History

The Company was incorporated on 1st July and obtained the Certificate

for Commencement of Business on October 15. It was promoted by K.R.

Rao, C.B. Rao, N. Subramanium, N. Sambasivam, N. R. Reddy, Dr. R.

Kailasam and Ms. R. Vijayalakshmi.

The Company undertook to set up a 100% EOU for manufacture of 90 TPA

of cephalosparin group.

A Collaboration agreement was entered into with sintofarm, Italy for

state-of-the-art technology, buy back of entire production, training of

personnel etc. Also, another agreement was entered into with M.V.

Reddy for know-how for manufacture of 7-ADCA & Cephalexin.

17,01,800 shares issued, subscribed & paid-up, (of these 14,38,000

shares subscribed for by signatories to the Memorandum of Association,

1,00,000 shares to NRI who are associates, friends of promoters and

1,63,800 shares to foreign collaboration sintofarm).

During September, the company issued 42,98,200 No. of equity shares

of Rs 10 each for cash at par of which the following were reserved for

allotment on a firm basis.

(1) 6,12,000 share to promoters, directors etc.

(2) 1,36,200 No. of equity shares to collaborators sintofarm in

repatriation basis.

(3) 5,50,000 shares to secured India Investment on repatriation

basis.

(4) 5,00,000 shares to IDBI. Balance 25,00,000 shares issued to the

public.

The Company entered into an agreement with SBD Laboratories Italy,

for technology for keeping production in sterile condition.

The Company undertook to expand the combined capacity of cephalexin,

cepadroxyl and cefradine from 90 tonnes to 150 tonnes.

14,73,000 shares allotted to FIIs domestic corporate bodies,

employees of the company on private placement basis. 12,00,000 No. of

equity shares allotted on private placement basis with Indian Mutual

Funds & others in July.

The Company proposed to set up a state-of-the-art formulation

facility exclusively for manufacture of sterile cephalosporin

formulations.

86,73,000 Rights equity shares issued (prop. 1:1; prem. Rs 30).

The company recently became the youngest Indian pharmaceutical

company to be awarded the ISO 9002 certification.

The company has tied up with Technology Innovative Industry of Italy.

The company has also launched a range of new products in the steriles

category during the last quarter of 1996-97. Five new products namely

Cefazolin Sodium, Cefradine Arginine, Cefradine Sodium Carbonate,

Cefonicid Sodium and Ceftazidime Sodium, have been introduced in the

market.

The company is the country's largest producer of oral and sterile

cephalosporins and has a global market share of 13 per cent with a

capacity of 480 tonnes per annum and among the top five in the world

for 7-ADCA (an intermediate) and oral cephalosprins based on 7-ADCA.

Orchid Chemicals & Pharmaceuticals Ltd (OCPL) is planning to

diversify into power generation by setting up either thermal or

hydraulic/wind/solar power plants.

OCPL, also proposes to establish a modern formulation facility

exclusively for manufacturing sterile Cephalosporin formulations.

The company has a technical collaboration with SBD Laboratories,

Italy for manufacture of ceftriaxone and cefotaxime and an alliance

with the Novartis group would translate into significant long-term

gains for the company.

Orchid Chemicals and Pharmaceuticals Ltd, the bulk producer of

cephalosporins, is entering the formulation market. The Drug

Controller of India has granted a licence to Cipla Ltd and Orchid

Pharmaceuticals and Chemicals to export sildenafil citrate, the bulk

drug that goes into Pfizer's patented anti-impotence pill Viagra.

Orchid Chemicals and Pharmaceuticals Ltd, the Chennai-based

export-oriented pharma company, will be commissioning its captive power

plant. The installed capacity of the plant is 6.76 MW.

Orchid, along with Cipla and Ranbaxy, had recently received approval

from the Drug Controller of India (DCI) for the manufacture and export

of sildenafil citrate, the main ingredient in Viagra, the drug

developed by Pfizer to treat human male erectile dysfunction.

Orchid Chemicals and Pharmaceuticals is keen to launch its branded

version of Pfizer's blockbuster anti-impotence drug, Viagra, in India.

The Chennai-based Orchid Pharmaceuticals & Chemicals has `more or

less' decided against acquiring Roussel India's bulk-cum-formulations

production facility at Thane in Maharashtra.

The company is setting up a new plant for non-cephalosporins bulk

drugs in Cuddalore in Tamil Nadu.

The initial range of products launched include three injectable

cephalosporin formulations and two coprescription analgesics of the

NSAID category. These are Tax-O-bid (Cefotaxime injection), Cefogram

(Ceftriaxone injection), Orzid (Ceftazidime injection), Orchidol

(Tramadol tablets) and N-Ltd (Nimesulide dispersible tablets.

It has proposed to launch cephalosporin antibiotics range of products

in July and August, including cefoperazone injection, cephalexin

capsules and cefadroxyl capsules and cefixme tablets and dry syrup. In

the fourth quarter of the current year two products for pain management

meloxicam and nimesulide tramadol variants will be introduced.

Orchid Chemicals and Pharmaceuticals Ltd has tied up with foreign

investors for funds to be invested in new technologies, research and

development, and facilities over the next five years.

Orchid Chemicals & Pharmaceuticals has announced an equity issue of

1.06 crore shares of Rs 10 each at a premium to mop us Rs 175 crore on

a private placement basis.

The company is collaborating with JSS College of Pharmacy in

Udhagamandalam in research projects to identify the active ingredients

in traditional herbal medicines.

The Chennai-based Orchid Chemicals & Pharmaceuticals is considering

joining the elite group of eight pharmaceutical companies who have

recently floated the Indian Pharmaceutical Association (IPA) a lobby to

influence government policy on the pharma industry.

Orchid Chemicals and Pharmaceuticals Ltd has signed a memorandum of

understanding (MoU) with the Mumbai-based Ajanta Pharma Ltd to acquire

the latter's bulk drugs manufacturing plant located at Aurangabad,

according to a company statement.

During the quarter under review five new products - one oral

cephalosporin Cefixime (under the brand name of Orfix), as also a

dispensible range of select cephalosporin antibiotics were launched.

Four anti-hypertensives Amiodipine, Lisinopril and combinations were

also launched.

A fire incident occured during the early hours on 16th January, in

one of the production blocks of Orchid's bulk drug manufacturing

facility at Althur, near Chennai.

The Company has been awarded the "Trophy for Excellent Performance in

Exports" as part of the National Export Awards Programme, 1998-99.

The Company has entered into a joint venture with the UK-based

Cambridge Chemicals to distribute its nutraceutical products in that

country.

The Company is setting up a new R&D facility to work on new drugs/new

variants on drugs and drug delivery systems at Alathur near Chennai.

Orchid Chemicals and Pharmaeuticals on May 24 informed the BSE that

the company has issued foreign currency convertible bonds to

International finance Corporation for $20m. The bonds will be converted

into equity shares at a price of Rs 220 a share within a period of 18

months from the date of allotment of bonds.

Orchid Chemicals & Pharmaceuticals Ltd (OCPL) proposes to expand the

strength of its board to 15 from the existing level of 14, aimed at

accommodating the representative of International Finance Corporation

(IFC).

Narayana Reddy resigns from the Board of Orchid Chemicals & Pharma.

Orchid Chemicals & Pharmaceuticals has inked a 50:50 joint venture alliance pact with a California-based drug discovery research firm Bexel Biotechnology Inc.

Orchid Chemicals & Pharmaceuticals Ltd on September 16, 2002 announced the induction of Mr RS Prasad as the Executive Director and Chief Operating Officer of Orchid Healthcare, its formulations division to fast-track its foray into the US and other regulated markets.

Orchid Chemicals & Pharmaceuticals Ltd has informed that IDBI had withdrawn the nomination of Shri S Gajendran and instead appointed Shri M V Badrinath as its nominee on the Board.

Orchid Chemicals & Pharmaceuticals Ltd informs that Mr A R Hedge Director and CEO Formulation is relinquishing the directorship in Orchid effective June 6, 2003 and Mr R S Prasad will be responsible for all technical and manufacturing activities of Orchid's formulation business and Mr S Vijayraghvan will be responsible for all sales and marketing activities of Orchid's formulation business.

Orchid acquires Mano Pharmaceuticals for a consideration of Rs.26cr.

Orchid receives formal approval from US Food and Drug Administration for Cephalaxin.

Orchid enters a new co-marketing concept and has signed a agreement with 4 companies

to boost its sales.

Orchid Chemicals Aurangabad facility awarded ISO 14001 and OHSAS 18001

Orchid gets Europe drug Authority nod

Orchid Chemicals & Pharmaceuticals granted CoS for Cefotaxime Sodium

Orchids inks pact with Par Pharmaceuticals Inc, to market oral cephalosporin formulations in US market

Orchid Chemicals & Pharmaceuticals Ltd forges alliance with US-based Par Pharmaceuticals to market oral cephalosporin antibiotics.

Orchid Chemicals & Pharmaceuticals Ltd (Orchid) has entered into an agreement with Apotex Inc for an exclusive marketing pact in the Canadian market.

Granted the Certificate of Suitability (CoS) by the European Directorate for the Quality of Medicines for its API product Cephradine

Orchid Chem enters into US market

Orchid pact with Alpharma Inc to market oral non-antibiotic formulations in US & European markets

Orchid enters into agreement with STADA Pharmaceuticals, Inc (USA)

Orchid Chemicals & Pharmaceuticals Ltd has received approval from USFDA for generic Ceftriaxone ANDA

Orchid Chemicals & Pharmaceuticals has given the Bonus in the Ratio of 1:2

Orchid signs deal with Biovitrum in drug discovery field.

Orchid Chemicals & Pharmaceuticals Ltd on February 20, 2008 has announced that it has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Cefuroxime Axetil Tablets. The product is available in three dosage strengths, 125 mg, 250 mg and 500 mg.

Orchid Chemicals and Pharmaceuticals Ltd and Merck & Co have forayed into research collaboration and licence agreement to discover, develop and commercialise molecules essential for the treatment of bacterial and fungal infections.

Orchid Chemicals & Pharmaceuticals received approval from the U.S. Food and Drug Administration (US FDA) for its abbreviated new drug applications (ANDAs) for Piperacillin and Tazobactam for injection and will launch these products in marketing and distribution partnership with Apotex in the U.S.

Collaborates with Alvogen to license and market its eight oral non-antibiotic generic formulations.

Acquires US-based marketing company Karalex Pharma, to strengthen its presence in the front-end US market and to reach its generic products to the US customers directly.

Orchid redeems FCCBs aggregating to USD 25.69 million.

Orchid's API Manufacturing facility at Alathur was awarded with OHSAS 18000 : 2007 (Occupational Health and Safety Management System) certification.

Orchid's drug discovery research initiative with Merck advances.

Orchid Pharma reports successful completion of Phase I study of its novel PDE4 inhibitor molecule, OCID 2987.

Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira for approximately US$ 200 million.

Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics.

Orchid receives US FDA approval for Eszopiclone Tablets ANDA.

Company has received approval from the US FDA for the Abbreviated New Drug Application (ANDA).

The Company has changed its name from Orchid Chemicals & Pharmaceuticals Ltd to Orchid Pharma Ltd.

Trading symbol of the Company has changed from ORCHIDCHEM to ORCHIDPHAR.

"Orchid receives final USFDA nod for Rasagiline generic formulation".

Orchid Pharma Limited launches INR 500 Crore Qualified Institutional Placement programme

Orchid Bio Pharma has been granted approval by Competent Authority under the Production Linked Incentive (PLI) Scheme for manufacturing of product 7 ACA.